| 3CLpro or Mpro | 3-Chymotrypsin-like protease or Main protease |
| ACE2 | Angiotensin-converting enzyme 2 |
| CC50 | Cytotoxic concentration of the compound that reduced cell viability to 50% |
| CoVs | Coronaviruses |
| DPP4 | Dipeptidyl-peptidase 4 |
| EC50 | Effective concentration of compound needed to inhibit 50% of cytopathic effect |
| fRhK-4 | Fetal rhesus kidney-4 |
| GL | Glycyrrhizin |
| HBV | Hepatitis B virus |
| HCoV | Human coronavirus |
| HCV | Hepatitis C virus |
| IBV | Infectious bronchitis virus |
| MD | Molecular dynamics |
| MERS-CoV | Middle East Respiratory Syndrome-CoV |
| MHV | Mouse hepatitis virus |
| ORF1a | Open reading frame 1a |
| ORF1b | Open reading frame 1b |
| PLpro | Papain-like protease 2 |
| PP1a | Polyprotein ia |
| PP1b | Polyprotein 1b |
| RdRp | RNA-dependent RNA polymerase |
| SARS-CoV | Severe Acute Respiratory Syndrome-CoV |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome-CoV-2 |
| SI | Selectivity index |
| TGEV | Transmissible gastroenteritis virus |